MYOS is a BioNutrition and BioTherapeutics company focused on development and commercialization of products that improve muscle health and reduce frailty.

MYOS is the owner of MYO-T12, the first clinically demonstrated natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards for muscle health.

Currently we market two Bionutritional products to the general public. Sales of these formulations — Myo-X and MYO-T12 — are being invested in our research and development program and to commercialize other Bionutritional products to treat muscle-related conditions.

We will seek to gain market share for our core branded product, MYO-X, powered by MYO-T12, in the marketplace by:

Establishing the safety and clinical benefit of our products through basic and clinical research

MYOS Corporation to Present Mechanism of Action Data at the Experimental Biology Conference-The Effect of Fortetropin(TM) on Anabolic and Catabolic Signaling in Skeletal MuscleClick here to see full press release.http://bit.ly/1EIcoYj﻿

The Effect of Fortetropin(TM) on Anabolic and Catabolic Signaling in Skeletal Muscle. CEDAR KNOLLS, NJ -- (Marketwired) -- 02/23/15 -- MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and ...

MYOS Corporation Research Selected to Be Presented at International Conference on Molecular and Cellular Biology.MYOS has developed a novel bioanalytical methodology for proteome mapping using multi-dimensional separations and accurate mass, high resolution mass spectrometry. This methodology has been used to study the early changes that take place in hen egg yolk upon fertilization at the proteomic-level and may also be useful for human proteome studies as well. Fertilized chicken egg yolk is the source of active proteins in ‪#‎Fortetropin‬™, a unique orally administered dietary supplement clinically shown to reduce serum myostatin levels and increase lean body mass and muscle thickness. Recently, MYOS has also demonstrated in preclinical studies that Fortetropin upregulates the mTOR pathway, an important pathway for the synthesis of muscle proteins, and down-regulates the ubiquitin pathway, a pathway involved in muscle protein degradation. MYOS is working to further characterize beneficial proteins, lipids and other bioactive molecules found in Fortetropin.Please click here to review full release. http://bit.ly/1CgYslg﻿